Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Hesterkamp

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Combinatorial Chemistry & High Throughput Screening|June 18, 2009
Novel MK2 inhibitors by fragment screeningOliver Keminer, Joachim Kraemer, Jan Kahmann, et al.
Biochemistry|October 6, 2009
Fragment-based discovery of BACE1 inhibitors using functional assaysRobert Godemann, James Madden, Joachim Krämer, et al.
Antibiotics (Basel, Switzerland)|July 27, 2022
The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in <i>Staphylococcus aureus</i>Jan Balansky, Kenneth Pfarr, Christiane Szekat, et al.
Chemmedchem|July 29, 2010
Discovery of a novel Hsp90 inhibitor by fragment linkingJohn J Barker, Oliver Barker, Stephen M Courtney, et al.
Pharmaceutics|August 26, 2022
In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin ATim Becker, Anna K Krome, Sahel Vahdati, et al.
Msphere|September 12, 2022
Potent <i>In Vitro</i> and <i>Ex Vivo</i> Anti-Gonococcal Activity of the RpoB Inhibitor Corallopyronin AJennifer L Edwards, Jacqueline T Balthazar, Danillo L A Esposito, et al.
Microbiology Spectrum|December 4, 2023
Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection modelsKatharina Rox, Rolf Jansen, Tadeja Lukežič, et al.
Antibiotics (Basel, Switzerland)|September 23, 2020
Amidochelocardin Overcomes Resistance Mechanisms Exerted on Tetracyclines and Natural ChelocardinFabienne Hennessen, Marcus Miethke, Nestor Zaburannyi, et al.
Natural Product Reports|June 22, 2022
Corallopyronin A: antimicrobial discovery to preclinical developmentAnna K Krome, Tim Becker, Stefan Kehraus, et al.
NPJ Vaccines|January 26, 2024
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansLeonie Mayer, Leonie M Weskamm, Anahita Fathi, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Combinatorial Chemistry & High Throughput Screening|June 18, 2009
Novel MK2 inhibitors by fragment screeningOliver Keminer, Joachim Kraemer, Jan Kahmann, et al.
Biochemistry|October 6, 2009
Fragment-based discovery of BACE1 inhibitors using functional assaysRobert Godemann, James Madden, Joachim Krämer, et al.
Antibiotics (Basel, Switzerland)|July 27, 2022
The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in <i>Staphylococcus aureus</i>Jan Balansky, Kenneth Pfarr, Christiane Szekat, et al.
Chemmedchem|July 29, 2010
Discovery of a novel Hsp90 inhibitor by fragment linkingJohn J Barker, Oliver Barker, Stephen M Courtney, et al.
Pharmaceutics|August 26, 2022
In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin ATim Becker, Anna K Krome, Sahel Vahdati, et al.
Msphere|September 12, 2022
Potent <i>In Vitro</i> and <i>Ex Vivo</i> Anti-Gonococcal Activity of the RpoB Inhibitor Corallopyronin AJennifer L Edwards, Jacqueline T Balthazar, Danillo L A Esposito, et al.
Microbiology Spectrum|December 4, 2023
Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection modelsKatharina Rox, Rolf Jansen, Tadeja Lukežič, et al.
Antibiotics (Basel, Switzerland)|September 23, 2020
Amidochelocardin Overcomes Resistance Mechanisms Exerted on Tetracyclines and Natural ChelocardinFabienne Hennessen, Marcus Miethke, Nestor Zaburannyi, et al.
Natural Product Reports|June 22, 2022
Corallopyronin A: antimicrobial discovery to preclinical developmentAnna K Krome, Tim Becker, Stefan Kehraus, et al.
NPJ Vaccines|January 26, 2024
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansLeonie Mayer, Leonie M Weskamm, Anahita Fathi, et al.
Pageof 3